Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q3 2019 · 10-Q
Revenue$3.85M$3.85M−73.5% vs Q3 2018 Net Income-$32.94M-$32.94MN/M vs Q3 2018 EPS Diluted-$0.66-$0.66N/M vs Q3 2018 Operating Income-$34,588,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,129,000N/M Margins · derivedOperating margin-898.9%−786.9 pt vs Q3 2018
Net margin-856.1%−751.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end